Chicharros USA - bolsa internacional

HMNY

De momento en el AH van bien, las he visto a 11.40. Pensé que las ibas a ensillar más abajo, será que hizo suelo en los 9$?, lo mismo se tira unos días subiendo.

HMNY

en caliente durante la sesión me dio la sensación de que hizo suelo en la zona de 8.85...me gusta la vela diaria...creo que puede haber rebote/gato hasta 12.50 por lo menos...así que si se puede intentaré aprovecharlo...con stop en cuanto se pueda....

a la piltra ciao zzzzzzzzzz

Gente de bien estoy observando que las empresas petroleras están pillando fuerza al calor de la subida de precios del petróleo, es un movimiento parecido al que hicieron las empresas del acero e hierro el año pasado cuando subió el precio del hierro muchas subieron un 100%y más, hay petroleras que ya han subido bastantes sobre todo las de menor deuda ahora quedan las que tienen más deuda que si sigue subiendo el precio del petróleo o se mantienen irá limpiando deuda y subiendo como la espuma, atentos, hay muchas yo pj estoy en DNR con buena posición porque la controlo pero hay ciento de ellas, merece la pena echarles un vistazo, opinión desde mi punto de vista no seguirme al pie de la letra jjjj

AVGR

Muy buen AH... cerrando casi a 0.40 con más de 800.000 títulos... a esperar mañana el PM que es lo importante... a ver si durante la sesión podemos ir saliendo todos.. o por lo menos, todos los que queramos...

DRWIQ http://www.dragonwavex.com/system/files/marcus_andersson_release_final_2_0.pdf

El jueves 26 nombraron al nuevo CEO y hoy han nombrado al nuevo vicepresidente ejecutivo de marketing y ventas.

ATOS
Atossa Genetics Announces Closing of $5.5 Million Common Stock Public Offering and Over-allotment Option
[30/10/17] 17:31:00
SEATTLE, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today the closing of its previously announced underwritten public offering of 11,500,000 shares of common stock at a public offering price of $0.44 per share, as well as a concurrent closing of 1,000,000 additional shares of common stock pursuant to the exercise in full of the over-allotment option granted to the underwriters.
Gross proceeds, before underwriting discounts and commissions and estimated offering costs, were approximately $5.5 million. Atossa intends to use the net proceeds for general corporate purposes.
Maxim Group LLC acted as sole book-running manager for the offering.
The securities described above were offered by Atossa pursuant to a registration statement (File No. 333-220572) previously filed and declared effective by the Securities and Exchange Commission (SEC). The shares were offered by means of a prospectus supplement and accompanying prospectus, forming part of the registration statement. A final prospectus supplement and accompanying prospectus relating to this offering was filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at 212-895-3745. Electronic copies of the final prospectus supplement and accompanying prospectus are also available on the website of the SEC at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
(O) 866 893-4927
[email protected]
Investor Relations Contact:
Scott Gordon
CoreIR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516 222-2560
[email protected]

ATOS
A ver si después de ésto le da por pegar el estirón ya

AVGR

Ya tiene PM, chicos, y por ahora.....